Table 1.

Patient characteristics, including calculated standardised uptake values and labelling indices for the respective lesions

Patient No	Sex	Age (y)	Weight (kg)	Resected lesions	18FDG (SUV)	18FLT (SUV)	LI (% MIB-1)
1	M	87	72	Primary (asc colon)	9.2	3.5	69
2	M	66	82	Peritoneal recurrence	7.6	3.3	60
				Peritoneal lesion†	7.8	—	23
3	F	78	54	Liver metastases 1*	5.5	—	19
				Liver metastases 2*	11	—	26
4	F	75	63	Primary (rectal)	9.6	4.8	70
				Liver metastases	3.7	9.1	87
5	M	62	85	Primary (caecal)	9.7	5.5	77
6	F	60	58	Liver metastases	3.7	4.8	73
7	M	59	70	Primary (trans colon)	8.5	2.9	67
8	F	54	55	Primary (rectal)	5.9	1.4	69
9	F	67	95	Peritoneal recurrence	4.5	2.6	75
10	M	71	65	Liver metastases	4.7	6.1	87

¹⁸FDG, ¹⁸F labelled 2-fluoro-2-deoxy-d-glucose; ¹⁸FLT, 3′-deoxy-3-fluorothymidine; SUVs, standardised uptake values; LI, labelling index.

*Those lesions seen as avid for ¹⁸FDG but not for ¹⁸FLT.

†Inflammatory lesions not demonstrating uptake for ¹⁸FLT.